Latanoprost Viatris

Latanoprost, the active ingredient in Latanoprost Viatris, is a prostaglandin analog presented as a ophthalmic solution for ocular use. It treats primary open-angle glaucoma and ocular hypertension by lowering intra‑ocular pressure. GNH USA supplies Latanoprost Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost acts on the ocular pressure regulation pathway and is indicated for several glaucoma‑related conditions. - Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers intra‑ocular pressure to prevent development of glaucoma. - Elevated intra‑ocular pressure: improves uveoscleral outflow to maintain normal pressure.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation change: gradual darkening of the iris. - Eye irritation or foreign‑body sensation. - Blurred vision: transient visual disturbance. - Dry eye: reduced tear film stability.

Serious or Rare Side Effects: - Severe ocular inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, itching, or rash around the eye. - Vision loss: sudden decrease in visual acuity. - Corneal edema: swelling of the cornea that may affect clarity.

Before prescribing Latanoprost, clinicians should consider several safety aspects. - Monitor intra‑ocular pressure: regular IOP measurements are essential. - Avoid use in active ocular infection: may exacerbate infection. - Do not wear contact lenses during treatment: can trap the solution. - Inform ophthalmologist of any planned ocular surgery: may affect healing. - Pregnancy and lactation: safety unknown, use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, requiring careful management.

Major Interactions (Avoid): - Concurrent use of multiple prostaglandin analogs: increased risk of ocular side effects. - Use with non‑steroidal anti‑inflammatory eye drops: may reduce efficacy.

Moderate Interactions (Monitor Closely):\n- Co‑administration with corticosteroid eye drops: possible attenuation of pressure‑lowering effect. - Systemic beta‑blockers: monitor IOP as additive pressure‑lowering may occur. - Use with other ocular hypotensives (e.g., timolol): adjust dosing to avoid excessive pressure reduction.